Laboratorio Reig Jofre, S.a. · BME:RJF
Laboratorio Reig Jofre — Reig Jofre — FY2025 Earnings Presentation
21 slides from Laboratorio Reig Jofre's earnings presentation, 2026
Slide 1: Financial Results 2025
FINANCIAL RESULTS 2025
Slide 2: Statement
STATEMENT This presentation does not contain confidential material and may include publicly available market information that has not been independently verified by Reig Jofre. This information is given in summary form and does not purport to be complete. The information contained in this presentati
Slide 3: → Key factors 2025 → Sales by Business Unit 2025 → International Growth
→ Key factors 2025 → Sales by Business Unit 2025 → International Growth → Results 2025 → EBITDA 2025 → Results statement and balance sheet for 2025 → RJF stock performance 3
Slide 4: Key Factors 2025
KEY FACTORS 2025 Investments in Innovation in Development and efficiency technology and consolidation of productivity and product own brand digitization EMINTECH – IPCEI Project International Adquisition of expansión Vertical integration Leanbio & Syna European Biotechnology Therapeutics subsidiaries
Slide 5: Vertical integration
Vertical Commitment to biotechnology Raw materials (drug substance), high value-added services integration Sed ut perspiciatis integrated with the finished product (drug product) of RJF On 1 December 2025, REIG JOFRE BIOTECNOLOGY ,a strategic growth segment, to respond with greater capacity, special
Slide 6: Emintech project - IPCEI
Emintech project - IPCEI Sed ut perspiciatis RJF is an associate €25M EMINTECH member of the project 13 million grant European IPCEI (January 2023- from CDTI Med4Cure project August 2026) Consistent with our nearly 100-year commitment to EMINTECH Project addresses two major global health challenges:
Slide 7: Sales by Business Unit 2025
SALES BY BUSINESS UNIT 2025 millions of euros SALES 2025 € 331 M (2%) 41% 36% 23% PHARMACEUTICAL SPECIALTY CONSUMER TECHNOLOGIES PHT PHARMACARE SPC HEALTHCARE CHC € 137 M / (10 % ) € 120 M / +4 % € 74 M / +3 % Antibiotics 48 M€ Dermatology 38 M€ ENT RJ 13 M€ (30 %) +18 % +1 % Injectables Forté Pharm
Slide 8: Sales by Business Unit 2025
SALES BY BUSINESS UNIT 2025 millions of euros SALES 2025 € 331 M (2%) 41% 36% 23% PHARMACEUTICAL SPECIALTY CONSUMER TECHNOLOGIES PHT PHARMACARE SPC HEALTHCARE CHC € 137 M / (10 % ) € 120 M / +4 % € 74 M / +3 % • Antibiotic sales fell by 30% due to planned • Dermatology grew by +18%, led by sales of
Slide 9: International Growth
INTERNATIONAL TOTAL PRESENCE Sed ut perspiciatis SALES 2025 Spain Rest of Sed ut perspiciatis Europe Rest of the world GROWTH SALES 2025 +70 COUNTRIES € 331 M € 137 M € 157 M 41% 48% € 37 M 11% (2 %) (2 %) (5 %) Asia 7% Rest of Europe 48% Rest of the world 4% RJF maintains its focus on global expans
Slide 10: Results 2025
RESULTS 2025 Sed ut perspiciatis SALES • Annual sales fell by 2% compared to 2024 due to a temporary decline in antibiotic production at Pharmaceutical Technologies, which was partially offset by growth in the Specialty Pharmacare and € 331.1 M (2%) Consumer Healthcare divisions, which grew by 4% and
Slide 11: EBITDA 2025
EBITDA 2025 Waterfall 2024 to 2025 millions of euros (20%) 38.1 38.1 4.1 30.5 (4.7) 0.2 (9.7) (3.8) (1.4) +11% 2024 Temporary Emintech Emintech Regulated price Catalyst: Syna and Organic 2025 Reduction Project project reduction for operational Leanbio, Growth in Antibiotic Grant costs Condrosan® exc
Slide 12: Income Statement
INCOME STATEMENT INCOME STATEMENT (thousand euros) 31/12/2025 31/12/2024 V% • Sales amounted to €331 million, down 2% compared to 2024 due to Turnover 331.097 338.895 (2%) a drop (-30%) in sales of antibiotics. Cost of sales (135.283) (140.147) (3%) • The associated gross margin was 59%, half a poin
Slide 13: Balance Sheet: Assets and Investments
BALANCE SHEET INVESTMENTS 2025: 34 M€ ASSETS AND INVESTMENTS Millions of euros LEANBIO PARTICIPATION BALANCE SHEET (thousand euros) 31/12/2025 31/12/2024 INDUSTRIAL 4 M€ CAPEX R&D&I Cost of sales 26.495 26.809 Other intangible assets 69.581 55.285 21 M€ ACTIVATION Property, plant and equipment 129.5
Slide 14: Balance Sheet
BALANCE SHEET millions of euros Non-current assets Movements from 31/12/2024 to 31/12/2025 +31% 5 4 25 199 38 • Progress in • Digitalisation development strategy to (25) investments, increase Intangibles • Toledo plant. 152 New line to particularly in productivity upgrade Syna’s €70 million • Net as
Slide 15: Balance Sheet: Liabilities and Debt
BALANCE SHEET GROSS FINANCIAL DEBT LIABILITIES AND DEBTS 20 111.6 DEBT LEASES APPLICATION IFRS 16 in millions of € BALANCE SHEET (thousand euros) 31/12/2025 31/12/2024 in millions of € TOTAL EQUITY 220.450 213.950 DEBT WITH CREDIT INSTITUTIONS + 91.6 OTHER PUBLIC BODIES in millions of € Capital gran
Slide 16: Balance Sheet: Gross Financial Debt
BALANCE SHEET millions of euros Gross Financial Debt Movements from 31/12/2024 to 31/12/2025 +66% 11 112 6 0 28 Business • Includes €6 million of • Transactions excluding Syna debt convertible into a with credit grant for the Emintech and Leanbio 67 institutions project as costs are • Leanbio and fo
Slide 17: Evolution of RJF Shares
EVOLUTION OF RJF YTD SHARES YTD 25 DEC VALUATION VOLUME CASH RJF (ISIN ES0165359029) €2.57/Share - 31/12/2025 maximum minimum 8.4 M €23.9 M €2.86/Share €3.31 /Share €2.48/Share Titles 2025 2025 Weighted average 10/06/2025 16/01/2025 33 k titles €94 k SHAREHOLDER COMPOSITION 2025 average daily daily
Slide 18: Save the Date
SAVE THE DATE Palacio de la Bolsa de Madrid Plaza de la Lealtad 1, Madrid WEBCAST en directo español/inglés Access: www.reigjofre.com
Slide 19: Alternative Performance Measures
ALTERNATIVE PERFORMANCE Management uses certain alternative performance measures in making financial, MEASURES operating and planning decisions, as well as to evaluate the performance of the Group and its subsidiaries. Management believes that these alternative performance measures provide additiona
Slide 20: Links and Complementary Information
LINKS AND INFORMATION → RESULTS WEBCAST COMPLEMENTARY https://reigjofre.com/es/inversores/webcasts/ https://reigjofre.com/es/inversores/presentaciones/ → SUBSCRIPTION CENTRE http://www.reigjofre.com/es/noticias/centro-suscripcion → INVESTORS FINANCIAL AND OTHER RELEVANT INFORMATION https://reigjofre
Slide 21: Thank You
THANK YOU Gran Capità 10 08970 Sant Joan Despí BARCELONA, SPAIN www.reigjofre.com Investor Relations investors@reigjofre.com